SCHEMBL3016738

SCHEMBL3016738

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4c(C(C)C)cc(C(C)C)cc4C(C)C)CC3)n2)cc1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
CNR1 P21554 1/20 0.35
ALDH1A1 P00352 2/20 0.35
DNM1L O00429 11/20 0.34
HRH3 Q9Y5N1 1/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
OGA O60502 2/20 0.33
GBA1 P04062 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006880 0.93 OGA (0.36) SMN1; SMN2ALDH1A1DNM1LHRH3MAPT
SCHEMBL3013690 0.92 FABP4 (0.37) SMN1; SMN2NPC1RAB9AALDH1A1HRH3
SCHEMBL3012900 0.92 DNM1L (0.37) ALDH1A1DNM1LHRH3KMT2AOGA
SCHEMBL3004088 0.92 ALDH1A1 (0.35) ALDH1A1DNM1LHRH3OGA
SCHEMBL3021693 0.91 OGA (0.34) ALDH1A1DNM1LHRH3KMT2AOGA
SCHEMBL3007229 0.91 ALDH1A1 (0.34) ALDH1A1DNM1LHRH3OGA
SCHEMBL3019284 0.90 DNM1L (0.35) ALDH1A1DNM1LHRH3MAPT
SCHEMBL3000434 0.90 RAB9A (0.38) SMN1; SMN2NPC1RAB9AALDH1A1HRH3
SCHEMBL3021020 0.89 AR (0.34) SMN1; SMN2NPC1RAB9AALDH1A1DNM1L
SCHEMBL3007372 0.89 MAPT (0.34) SMN1; SMN2NPC1RAB9AHRH3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885NPC1 15/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.